August 2025
1. OGUNTALA JO, Yan AT
   Toward Evidence-Based Transfusion for Anemia in Acute Myocardial Infarction: Still an Unfinished Story.
   Ann Intern Med. 2025 Aug 19. doi: 10.7326/ANNALS-25-02486.
   

   >> Share

   
   July 2025
2. ABRAMOV D, Van Spall HGC
   In HF with iron deficiency, IV ferric carboxymaltose did not reduce a composite of first HF hospitalization or CV death at a median 17 mo.
   Ann Intern Med. 2025;178:JC82.
   

   >> Share

   
   March 2025
3. OGUNTALA JO, Yan AT
   In acute MI and acute or chronic anemia, liberal vs. restrictive transfusion did not affect recurrent MI or death.
   Ann Intern Med. 2025 Mar 4. doi: 10.7326/ANNALS-25-00161.
   

   >> Share

   
   November 2024
4. MALIK A, Martin GS
   In adults with TBI and anemia, liberal vs. restrictive RBC transfusion did not reduce unfavorable neurologic outcomes by 10% at 6 mo.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02456.
   

   >> Share

   
   October 2024
5. PORTELA GT, Carson JL, Swanson SA, Alexander JH, et al
   Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial Data.
   Ann Intern Med. 2024 Oct 1. doi: 10.7326/M24-0571.
   

   >> Share

   
   June 2024
6. FLYNN DJ, Feuerstein JD
   In transfusion-dependent, angiodysplasia-related anemia, adding octreotide to usual care reduced transfusions at 1 y.
   Ann Intern Med. 2024 Jun 4. doi: 10.7326/ANNALS-24-00517.
   

   >> Share

   
   May 2024
7. WEITZ HH, Merli GJ, Carson JL
   Web Exclusive. Annals Consult Guys - Acute Coronary Syndrome and Anemia: When to Transfuse?
   Ann Intern Med. 2024;177:eW240002.
   

   >> Share

   
   March 2024
8. MUKHERJEE D
   In acute MI and anemia, restrictive vs. liberal transfusion did not differ for a composite of recurrent MI or death at 30 d.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0010.
   

   >> Share

   
   February 2024
9. BASU A, Winn AN, Johnson KM, Jiao B, et al
   Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.
   Ann Intern Med. 2024;177:155-164.
   

   >> Share

   
   January 2024
10. WESEVICH A, Peek ME, Ratain MJ
    An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
    Ann Intern Med. 2024;177:85-86.
    

    >> Share

    
    October 2023
11. CARLIN S, Eikelboom JW
    In healthy older adults, low-dose aspirin increased incident anemia at a median 4.7 y.
    Ann Intern Med. 2023 Oct 3. doi: 10.7326/J23-0075.
    

    >> Share

    
    September 2023
12. CENTOR RM, McQuilten ZK
    Web Exclusive. Annals On Call - Low-Dose Aspirin and Iron Deficiency Anemia.
    Ann Intern Med. 2023;176:eA220018.
    

    >> Share

    
    July 2023
13. 
    Correction: Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly.
    Ann Intern Med. 2023 Jul 25. doi: 10.7326/L23-0274.
    

    >> Share

    
    June 2023
14. MCQUILTEN ZK, Thao LTP, Pasricha SR, Artz AS, et al
    Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial.
    Ann Intern Med. 2023 Jun 20. doi: 10.7326/M23-0675.
    

    >> Share

    
    
15. GOSHUA G, Calhoun C, Ito S, James LP, et al
    Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
    Ann Intern Med. 2023;176:779-787.
    

    >> Share

    
    April 2023
16. LERMAN JB, Newby LK
    In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death.
    Ann Intern Med. 2023;176:JC40.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share